Japan · Delayed Price · Currency is JPY SanBio Company Company Description
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system.
It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan.
The company’s research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
The company was founded in 2001 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Keita Mori |
Contact Details
Address: St. Luke Tower Tokyo, 104-0044 Japan | |
| Phone | 81 3 6264 3481 |
| Website | sanbio.com |
Stock Details
| Ticker Symbol | 4592 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | February - January |
| Reporting Currency | JPY |
| ISIN Number | JP3336750009 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Keita Mori | Chief Executive Officer |